This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, G. K. Search for Related Content PubMed PubMed Citation Articles by Schwartz, G. K. Social Bookmarking                            What's this?

Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy

Gary K. Schwartz

From the Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, and The Laboratory of New Drug Development; Memorial Sloan- Kettering Cancer Center, New York, NY

Address reprint requests to Gary K. Schwartz, MD, Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10021; e-mail: schwartg{at}mskcc.org.

The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate. An essential part of the cell cycle machinery is the cyclin-dependent kinases (CDKs). When activated, the CDKs provide a means for the cell to move from one phase of the cell cycle to the next (G1 to S or G2 to M). The cell cycle serves to protect the cell from genotoxic stress. In the setting of DNA damage, the CDKs are inhibited and the cell undergoes cell-cycle arrest. This provides the cell the opportunity to repair its own damaged DNA before it resumes cell proliferation. If a cell continues to cycle with its damaged DNA intact, the apoptotic machinery is triggered and the cell will undergo apoptosis. In essence, cell cycle arrest at these critical checkpoints represents a survival mechanism, which provides the tumor cell the opportunity to escape the effects of lethal DNA damage induced by chemotherapy. Over the past several years, a series of new targeted agents has been developed that promote apoptosis of DNA damaged tumor cells either during cell cycle arrest or following premature cell cycle checkpoint exit, such that tumor cells re-enter the cell cycle before DNA repair is complete. An understanding of the cell cycle and its relationship to p53 are critical for the successful clinical development of these agents for the treatment of patients with gastrointestinal cancers.

Supported by grant R01 CA 067819 from the National Cancer Institute, Bethesda, MD.

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. A. Parsels, M. A. Morgan, D. M. Tanska, J. D. Parsels, B. D. Palmer, R. J. Booth, W. A. Denny, C. E. Canman, A. J. Kraker, T. S. Lawrence, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol. Cancer Ther., January 1, 2009; 8(1): 45 - 54. [Abstract] [Full Text] [PDF]

				L. Fini, E. Hotchkiss, V. Fogliano, G. Graziani, M. Romano, E. B. De Vol, H. Qin, M. Selgrad, C.R. Boland, and L. Ricciardiello Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines Carcinogenesis, January 1, 2008; 29(1): 139 - 146. [Abstract] [Full Text] [PDF]

				M.N. Fornier, D. Rathkopf, M. Shah, S. Patil, E. O'Reilly, A.N. Tse, C. Hudis, R. Lefkowitz, D.P. Kelsen, and G.K. Schwartz Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5841 - 5846. [Abstract] [Full Text] [PDF]

				F. Perrone, S. Suardi, E. Pastore, P. Casieri, M. Orsenigo, S. Caramuta, G. Dagrada, M. Losa, L. Licitra, P. Bossi, et al. Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6643 - 6651. [Abstract] [Full Text] [PDF]

				W. J. Chng, R. F. Schop, T. Price-Troska, I. Ghobrial, N. Kay, D. F. Jelinek, M. A. Gertz, A. Dispenzieri, M. Lacy, R. A. Kyle, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma Blood, October 15, 2006; 108(8): 2755 - 2763. [Abstract] [Full Text] [PDF]

				R. J.C. Slebos, Y. Yi, K. Ely, J. Carter, A. Evjen, X. Zhang, Y. Shyr, B. M. Murphy, A. J. Cmelak, B. B. Burkey, et al. Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., February 1, 2006; 12(3): 701 - 709. [Abstract] [Full Text] [PDF]